Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE

Clinical trial NCT06607276 · RECRUITING

Trial details

NCT number

NCT06607276

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Status

RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2024-09-20

Primary completion

2026-09-20

Enrollment

122

View on ClinicalTrials.gov